Your browser doesn't support javascript.
loading
Immunoglobulin A Vasculitis Following COVID-19: A French Multicenter Case Series.
Ramdani, Yanis; Galempoix, Jean Marc; Augusto, Jean François; Dekmeer, Eva; Perard, Laurent; Ferreira, Nicole; Bigot, Adrien; Magnant, Julie; Jobard, Stéphanie; Diot, Elisabeth; Besse, Marie Charlotte; Henrique, Hélène; Maillot, François; Audemard-Verger, Alexandra.
Affiliation
  • Ramdani Y; Y. Ramdani, MD, F. Maillot, MD, PhD, A. Audemard-Verger, MD, PhD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, and University of Tours, Tours.
  • Galempoix JM; J.M. Galempoix, MD, Department of Internal Medicine, Nord Ardennes Hospital, Charleville-Mézières.
  • Augusto JF; J.F. Augusto, MD, PhD, Department of Nephrology, Angers University Hospital, Angers.
  • Dekmeer E; E. Dekmeer, MD, Department of Dermatology, Archet University Hospital, Nice.
  • Perard L; L. Perard, MD, Department of Internal Medicine, St Joseph-St Luc Hospital, Lyon.
  • Ferreira N; N. Ferreira, MD, A. Bigot, MD, J. Magnant, MD, S. Jobard, MD, E. Diot, MD, PhD, M.C. Besse, MD, H. Henrique, MD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, Tours, France.
  • Bigot A; N. Ferreira, MD, A. Bigot, MD, J. Magnant, MD, S. Jobard, MD, E. Diot, MD, PhD, M.C. Besse, MD, H. Henrique, MD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, Tours, France.
  • Magnant J; N. Ferreira, MD, A. Bigot, MD, J. Magnant, MD, S. Jobard, MD, E. Diot, MD, PhD, M.C. Besse, MD, H. Henrique, MD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, Tours, France.
  • Jobard S; N. Ferreira, MD, A. Bigot, MD, J. Magnant, MD, S. Jobard, MD, E. Diot, MD, PhD, M.C. Besse, MD, H. Henrique, MD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, Tours, France.
  • Diot E; N. Ferreira, MD, A. Bigot, MD, J. Magnant, MD, S. Jobard, MD, E. Diot, MD, PhD, M.C. Besse, MD, H. Henrique, MD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, Tours, France.
  • Besse MC; N. Ferreira, MD, A. Bigot, MD, J. Magnant, MD, S. Jobard, MD, E. Diot, MD, PhD, M.C. Besse, MD, H. Henrique, MD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, Tours, France.
  • Henrique H; N. Ferreira, MD, A. Bigot, MD, J. Magnant, MD, S. Jobard, MD, E. Diot, MD, PhD, M.C. Besse, MD, H. Henrique, MD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, Tours, France.
  • Maillot F; Y. Ramdani, MD, F. Maillot, MD, PhD, A. Audemard-Verger, MD, PhD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, and University of Tours, Tours.
  • Audemard-Verger A; Y. Ramdani, MD, F. Maillot, MD, PhD, A. Audemard-Verger, MD, PhD, Department of Internal Medicine and Clinical Immunology, University Hospital of Tours, and University of Tours, Tours.
J Rheumatol ; 49(12): 1390-1394, 2022 12.
Article in En | MEDLINE | ID: mdl-36243405
OBJECTIVE: Immunoglobulin A vasculitis (IgAV) usually occurs following viral respiratory tract infection. In the context of the global coronavirus disease 2019 (COVID-19) pandemic, we describe a case series of patients who developed IgAV following SARS-CoV-2 infection. METHODS: This national multicenter retrospective study included patients with IgAV following SARS-CoV-2 infection from January 1, 2020, to January 1, 2022. Patients had histologically proven IgAV and reverse transcription PCR (RT-PCR)-proven SARS-CoV-2 infection. The interval between infection and vasculitis onset had to be < 4 weeks. RESULTS: We included 5 patients, 4 of whom were women with a mean age of 45 years. Four patients had paucisymptomatic infections and 1 required a 48-hour low-flow oxygen treatment. All 5 patients had purpuric skin involvement. Arthritis was observed in 2 patients, 3 had IgA glomerulonephritis, and 2 had digestive involvement. Three renal biopsies were performed and showed mesangial IgA deposits without any extracapillary proliferation. Median C-reactive protein was 180 (range 15.1-225) mg/L, median serum creatinine level was 65 (range 41-169) µmol/L, and 2 patients had a glomerular filtration rate < 60 mL/min. Four patients received first-line treatment with glucocorticoids. All patients had a favorable progression and 2 patients experienced minor skin relapses, one after COVID-19 vaccination. CONCLUSION: This series describes the emergence of IgAV closely following COVID-19; we were not able to eliminate an incidental link between these events. Their disease outcomes were favorable. In most of our patients, the SARS-CoV-2 infection was paucisymptomatic, and we recommend RT-PCR tests to look for COVID-19 in patients without any evident triggers for IgAV.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: IgA Vasculitis / Vasculitis / COVID-19 Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: J Rheumatol Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: IgA Vasculitis / Vasculitis / COVID-19 Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: J Rheumatol Year: 2022 Type: Article